ARTICANZ - Beta (ver 0.9)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/ALK/RET-inhibitor
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/ALK/RET-inhibitor
2
trial(s) found.
NCT06624059
Curative
Phase 3
Recruiting
A Phase I-III, Multicenter Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Patients With Resectable Stage I-III Non-Small Cell Lung Cancer, Selected According to Biomarker Status (
HORIZON-2
)
ALK/RET inhibitor
ALK inhibitor
ALK inhibitor,second generation
Alectinib
Carboplatin
Cisplatin
Pemetrexed
RET inhibitor
antimetabolite
cancer therapy
cancer therapy,ALK-targeting
cancer therapy,RET-targeting
cytotoxic chemotherapy
platinum-based antineoplastic agent
+ ALK/RET inhibitor
Non-small cell lung cancer
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT05170204
Curative
Phase 3
Recruiting
A Phase I-III, Multicenter Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Patients Selected According to Biomarker Status, With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (
BO42777
)
ALK/RET inhibitor
ALK inhibitor
ALK inhibitor,second generation
ALK inhibitor,third generation
Alectinib
Durvalumab
Entrectinib
RET inhibitor
ROS1 inhibitor
TRK inhibitor
TRK inhibitor,first generation
anti-PD-L1 monoclonal antibody
cancer therapy
cancer therapy,ALK-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PD-L1-targeting
cancer therapy,RET-targeting
cancer therapy,ROS1-targeting
cancer therapy,TRK-targeting
immune checkpoint blockade
immune checkpoint blockade,PD-L1-targeting
immuno-oncology therapy,PD-L1-targeting
+ ALK/RET inhibitor
Non-small cell lung cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - GenesisCare North Shore Private Hospital (WITHDRAWN)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (WITHDRAWN)
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
WA
6009 - Nedlands - One Clinical Research
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (2)
Recruitment Country and State
NSW (2)
VIC (2)
WA (2)
NZ (1)
Phase
Phase 3 (2)
Trial Type
Curative (2)
Cancer Therapy Class
ALK
100%
RET
100%
PD-1/PD-L1
50%
PD-L1
50%
ROS1
50%
TRK
50%
Facility
3000 - Melbourne - Peter MacCallum Cancer Centre (2)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (1)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (1)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (1)
2050 - Camperdown - Chris O'Brien Lifehouse (1)
2065 - St Leonards - GenesisCare North Shore Private Hospital (1)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (1)
6009 - Nedlands - One Clinical Research (1)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (1)
Cancer Type
Cancer
Lung cancer
Non-small cell lung cancer
Respiratory tract cancer
Solid tumour
Thoracic cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy